Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by SizzlinSteakson May 24, 2018 10:51am

214 Views

Post# 28075049

Clearly

This stock is under accumulation.

My guess is we trade sideways for a while longer, with a very gradual increase in share price and we will hit a tipping point and start to move higher.....or the company will announce a partnership with one of the many potential pharmaceutical companies and we will start to rocket northbound.

We shall see... but as usual we are under control of the market makers and short term price fluctuaitons are difficult to predict.

Bullboard Posts

NervGen Pharma: Proof that NVG-291 works?